Journal Club

Speakers: 

Evan Liddington, PharmD, PGY2 Hematology/Oncology Resident - has nothing to disclose.

Alexis Fanshier, PharmD, PGY2 Hematology/Oncology Resident - has nothing to disclose.

Moderator: 

Tristan Maiers, PharmD, BCOP, PGY2 Oncology Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the role of AXL receptor tyrosine kinase in the pathophysiology and treatment resistance of acute myeloid leukemia (AML).

  Analyze the safety, tolerability, and efficacy outcomes of bemcentinib monotherapy and in combination with low-dose cytarabine in patients unfit for intensive chemotherapy.

  Evaluate the potential clinical implications of bemcentinib in treating AML, including its place relative to current guideline-recommended therapies.

• •Discuss clinical significance of ESR1 mutations and impacts on therapy

  •Review current recommendations for HR-positive, HER2-negative advanced breast cancer

  •Evaluate results of camizestrant use from the SERENA-6 trial

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP; Rajiv Panikkar, MD; Michele Long, BSN; Jaime Weeder, NP and Christopher Kashi, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None